Disease-Vaccine-Landing-Page

Pfizer reports that the vaccine efficacy in infants born from mothers who received the RSV vaccine during the third trimester of pregnancy was 57.1 percent at 90 days after birth,...

In the pre-licensing clinical trial, Pfizer reported vaccine efficacy to be 66.7 percent against the first episode of RSV-related lower respiratory tract infection with two or more symptoms, and had...

On July 17, 2023 the FDA approved the drug nirsevimab under the trade name Beyfortus, a monoclonal antibody, for the prevention of RSV. Though the CDC has determined that it...

On May 31, 2024, the FDA approved MRESVIA, an mRNA RSV vaccine manufactured by Moderna, for use in persons 60 years of age and older. The approval of MRESVIA was...

In August 2022, Pfizer issued a press release announcing the success of their Phase 3 clinical trial of a bivalent RSV prefusion F vaccine candidate, RSVpreF, in persons 60 years...

In October 2022, GlaxoSmithKline (GSK) pharmaceutical issued a press release that reported their RSV vaccine reduced severe RSV illness by 94.1 percent in persons 60 years and older. GSK also...

Contraindications to receiving CAPVAXIVE (PCV21) vaccine documented in Merck’s package insert include a previous severe allergic reaction or anaphylaxis to any component of PCV21 or any vaccine containing diphtheria toxoid.Data...

According to the CAPVAXIVE (PCV21) package insert, in pre-licensing clinical trials, the most commonly reported side effects following vaccination included injection site pain, redness and swelling, muscle pain, headache, and...

CAPVAXIVE (PCV21), manufactured by Merck, was approved by the FDA through an accelerated approval process, in June 2024. According to the manufacturer, in adults 50 years and older, PCV21 targets...

CAPVAXIVE is a 21-valent pneumococcal conjugate vaccine (PCV) manufactured by Merck Sharp & Dohme Corp. containing S. pneumonia serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B (deOAc...